Novartis Drug
- All
- News
- Videos
-
Novartis Pharma Signs World's 1st Licensing Deal For Cancer Drug
Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Gujarat Couple Raise Rs 16 Crore For 1 Injection To Save 5-Month-Old Son
A couple from Gujarat has raised Rs 16 crore with the help of a crowdfunding platform to buy a gene therapy injection for the treatment of their 5-month-old son suffering from spinal muscular atrophy, a rare genetic disorder.
-
Just Approved Gene Therapy Drug Is World's Most Expensive At $2.1 Million
The Food and Drug Administration on Friday approved the most expensive drug in the world, a $2.1 million, one-time gene therapy for treatment of a rare disease that afflicts infants.
-
Swiss Pharmaceutical Giant Novartis To Inject $100 Million Into New Treatments For Malaria
Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 people in 2016.
-
India-Origin Vasant Narasimhan Named CEO Of Novartis
Vasant Narasimhan is among a new generation of leaders at Novartis who have sought to improve the process in which drugs move from research to actually becoming a commercial product.
-
Compound Found To Treat 3 Parasitic Tropical Diseases
In a study published in the journal Nature, scientists at the Genomics Institute of the Novartis Research Foundation found the compound can cure all three diseases in mice, and does not harm normal human cells in laboratory tests.
-
New Heart Drugs Struggle To Win Sales As Doctors Hold Back
New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine today.
-
Drug Defies A Rare Form Of Cancer - And Market Logic
When the drug company Novartis launched its breakthrough cancer medicine, Gleevec, in 2001, the list price was $26,400 a year. The company's chief executive acknowledged it was expensive, calling it an "uphill battle to win understanding for our decision."
-
Novartis Japan Hit With Suspension Over Side-Effect Reporting
Japanese health authorities said today that they have ordered the local unit of Swiss pharmaceutical giant Novartis to temporarily suspend its operations for failing to report drug side effects.
-
Heart Drug Could Be "Most Exciting Ever", Says Novartis
Swiss drugmaker Novartis has unveiled strikingly good clinical trial results for a new heart failure drug that might be the biggest pharmaceutical advance in a quarter of century.
-
US lawsuit accuses Novartis of health care fraud
The US government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.
-
India defends rejection of Novartis patent bid
An Indian court was fully justified to reject a patent bid by Swiss drug giant Novartis last week, India's trade and industry minister insisted in Geneva on Monday, defending the country's generic drug business.
-
Novartis on patent setback: Will continue to invest in India, but cautiously
Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Novartis Pharma Signs World's 1st Licensing Deal For Cancer Drug
Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Gujarat Couple Raise Rs 16 Crore For 1 Injection To Save 5-Month-Old Son
A couple from Gujarat has raised Rs 16 crore with the help of a crowdfunding platform to buy a gene therapy injection for the treatment of their 5-month-old son suffering from spinal muscular atrophy, a rare genetic disorder.
-
Just Approved Gene Therapy Drug Is World's Most Expensive At $2.1 Million
The Food and Drug Administration on Friday approved the most expensive drug in the world, a $2.1 million, one-time gene therapy for treatment of a rare disease that afflicts infants.
-
Swiss Pharmaceutical Giant Novartis To Inject $100 Million Into New Treatments For Malaria
Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 people in 2016.
-
India-Origin Vasant Narasimhan Named CEO Of Novartis
Vasant Narasimhan is among a new generation of leaders at Novartis who have sought to improve the process in which drugs move from research to actually becoming a commercial product.
-
Compound Found To Treat 3 Parasitic Tropical Diseases
In a study published in the journal Nature, scientists at the Genomics Institute of the Novartis Research Foundation found the compound can cure all three diseases in mice, and does not harm normal human cells in laboratory tests.
-
New Heart Drugs Struggle To Win Sales As Doctors Hold Back
New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine today.
-
Drug Defies A Rare Form Of Cancer - And Market Logic
When the drug company Novartis launched its breakthrough cancer medicine, Gleevec, in 2001, the list price was $26,400 a year. The company's chief executive acknowledged it was expensive, calling it an "uphill battle to win understanding for our decision."
-
Novartis Japan Hit With Suspension Over Side-Effect Reporting
Japanese health authorities said today that they have ordered the local unit of Swiss pharmaceutical giant Novartis to temporarily suspend its operations for failing to report drug side effects.
-
Heart Drug Could Be "Most Exciting Ever", Says Novartis
Swiss drugmaker Novartis has unveiled strikingly good clinical trial results for a new heart failure drug that might be the biggest pharmaceutical advance in a quarter of century.
-
US lawsuit accuses Novartis of health care fraud
The US government sued Novartis Pharmaceuticals Corp. Tuesday, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own.
-
India defends rejection of Novartis patent bid
An Indian court was fully justified to reject a patent bid by Swiss drug giant Novartis last week, India's trade and industry minister insisted in Geneva on Monday, defending the country's generic drug business.
-
Novartis on patent setback: Will continue to invest in India, but cautiously
Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
